Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd (KPL) last traded at ₹3,374, a market capitalisation of ₹3,501 crore, on a P/E of 42.8. Over the past 52 weeks the stock has ranged between ₹829 and ₹3,744. Kwality Pharmaceuticals Ltd last reported results for the quarter ended Jun 2026, with sales of ₹162 crore and net profit of ₹26 crore. Kwality Pharmaceuticals Ltd’s annual general meeting is scheduled for 25 Aug 2026. Figures are as of 25 Aug 2026 and are not real time.
Kwality Pharmaceuticals Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Kwality Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹162 cr, up 45.9% from ₹111 cr a year earlier. Net profit was ₹26 cr, up 116.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 90 | 84 | 116 | 111 | 111 | 123 | 157 | 162 |
| Expenses | 70 | 67 | 90 | 87 | 86 | 93 | 118 | 121 |
| Operating profit | 20 | 18 | 26 | 24 | 25 | 30 | 39 | 41 |
| OPM % | 22% | 21% | 22% | 22% | 23% | 24% | 25% | 25% |
| Other income | 0 | 1 | 1 | 0 | 1 | -0 | 1 | 1 |
| Interest | 3 | 2 | 2 | 3 | 3 | 2 | 3 | 3 |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Profit before tax | 13 | 11 | 19 | 17 | 18 | 22 | 32 | 34 |
| Tax % | 33% | 25% | 24% | 30% | 23% | 28% | 20% | 25% |
| Net profit | 8 | 9 | 14 | 12 | 14 | 16 | 25 | 26 |
| EPS (₹) | 8.16 | 8.22 | 13.96 | 11.50 | 13.61 | 15.43 | 24.38 | 24.69 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Kwality Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 262 | 456 | 251 | 307 | 370 | 503 | 554 |
| Operating profit | 29 | 172 | 61 | 66 | 80 | 118 | 135 |
| OPM % | 11% | 38% | 24% | 22% | 22% | 24% | 24% |
| Net profit | 15 | 120 | 19 | 24 | 40 | 67 | 81 |
| EPS (₹) | 14.60 | 115.64 | 18.67 | 22.94 | 38.41 | 64.91 | 78.11 |
TTM is the trailing twelve months to the most recent quarter.
Kwality Pharmaceuticals Ltd growth and returns
- 10 Years
- 21%
- 5 Years
- 14%
- 3 Years
- 26%
- TTM
- 38%
- 10 Years
- 44%
- 5 Years
- 35%
- 3 Years
- 29%
- TTM
- 88%
- 10 Years
- 65%
- 5 Years
- 51%
- 3 Years
- 108%
- 1 Year
- 241%
- 10 Years
- 26%
- 5 Years
- 27%
- 3 Years
- 18%
- Last Year
- 23%
Kwality Pharmaceuticals Ltd shareholding pattern
Promoters held 54.86% at Jun 2026, broadly unchanged since Jun 2025. FIIs 3.13% and DIIs 0.56%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 54.82% | 54.82% | 54.82% | 54.82% | 54.82% | 54.82% | 54.87% | 54.86% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.50% | 2.79% | 3.13% |
| DIIs | 0.02% | 0.03% | 0.32% | 0.33% | 0.33% | 0.33% | 0.36% | 0.56% |
| Public | 45.15% | 45.14% | 44.86% | 44.86% | 44.83% | 44.33% | 41.99% | 41.45% |
| No. of shareholders | 7,487 | 8,947 | 9,420 | 10,115 | 11,595 | 10,709 | 10,555 | 13,279 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Kwality Pharmaceuticals Ltd’s AGM?
Kwality Pharmaceuticals Ltd’s annual general meeting is scheduled for 25 Aug 2026.
- AGM43rd Annual General Meeting and E-voting
- AGM43rd Annual General Meeting and related resolutions
See the full results calendar for every Indian company reporting in the next 30 days.
Kwality Pharmaceuticals Ltd corporate filings
- Newspaper Publication of Unaudited Financial Results for the quarter ended June 30, 2026.Company Updatehigh impact
Cruxal's analysis: Kwality Pharmaceuticals Limited has reported robust financial results for the quarter…
Read the full analysis - Newspaper Publication of Notice of 43rd Annual General Meeting.Company Updatelow impact
Cruxal's analysis: Kwality Pharmaceuticals has published a newspaper notice regarding its 43rd Annual…
Read the full analysis - Outcome of Investors/Analysts Meeting held on August 10, 2026Company Updatelow impact
Cruxal's analysis: Kwality Pharmaceuticals held an investor and analyst meeting on August 10, 2026. The…
Read the full analysis - Transcript of Earnings Conference Call - Q1FY27Company Updatehigh impact
Cruxal's analysis: Kwality Pharmaceuticals Limited management, led by CFO Aditya Arora, reaffirmed strong…
Read the full analysis - Investor Presentation for quarter ended June 30, 2026.Company Updatehigh impact
Cruxal's analysis: Kwality Pharmaceuticals Ltd. has upwardly revised its FY27 revenue guidance to over 700…
Read the full analysis - Submission of standalone and consolidated unaudited financial results for the quarter ended on 30.06.2026 under Regulation 33 of the SEBI (LODR) Regulations, 2015Board Meetinghigh impact
Cruxal's analysis: Kwality Pharmaceuticals Limited delivered a robust performance for the quarter ended June…
Read the full analysis - NOTICE OF 43RD AGM IS ENCLOSEDAGM/EGMhigh impact
Cruxal's analysis: Kwality Pharmaceuticals Limited reported a strong FY26, with consolidated revenue from…
Read the full analysis - Pursuant to Regulations 30 and 34 of the SEBI (LODR) Regulations, 2015, as amended ('' Listing Regulations''), please find attached herewith the Annual Report of the Company for the FY ....Otherslow impact
Cruxal's analysis: Kwality Pharmaceuticals has released its Annual Report for the financial year 2025-26 and…
Read the full analysis - Intimation of Book Closure.Company Updatelow impact
Cruxal's analysis: Kwality Pharmaceuticals Ltd has issued an intimation regarding the closure of its…
Read the full analysis - Intimation of 43rd AGMCompany Updatelow impact
Cruxal's analysis: Kwality Pharmaceuticals Limited has formally intimated the BSE regarding the scheduling…
Read the full analysis - This is to inform you, pursuant to Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the Board of Directors ....Otherslow impact
Cruxal's analysis: Kwality Pharmaceuticals Limited has announced the scheduling of its 43rd Annual General…
Read the full analysis - Intimation of Earnings Conference Call for Q1 FY 2026-27Company Updatelow impact
Cruxal's analysis: Kwality Pharmaceuticals Limited has announced an Earnings Conference Call for Q1 FY…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Kwality Pharmaceuticals Ltd
Cruxal reads every Kwality Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.